These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37231725)

  • 1. An Update on the Effect Of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Clinical Trials.
    Alfayez AI; Alfallaj JM; Mobark MA; Alalwan AA; Alfayez OM
    Curr Diabetes Rev; 2024; 20(2):e250523217349. PubMed ID: 37231725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence.
    Yabiku K
    Front Endocrinol (Lausanne); 2021; 12():768850. PubMed ID: 34950104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review.
    Raj H; Durgia H; Palui R; Kamalanathan S; Selvarajan S; Kar SS; Sahoo J
    World J Diabetes; 2019 Feb; 10(2):114-132. PubMed ID: 30788048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mendelian randomisation reveals Sodium-glucose Cotransporter-1 inhibition's potential in reducing Non-Alcoholic Fatty Liver Disease risk.
    Dobbie LJ; Cuthbertson DJ; Hydes TJ; Alam U; Zhao SS
    Eur J Endocrinol; 2023 Jun; 188(6):K33-K37. PubMed ID: 37343141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
    Dougherty JA; Guirguis E; Thornby KA
    Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Xing B; Zhao Y; Dong B; Zhou Y; Lv W; Zhao W
    J Diabetes Investig; 2020 Sep; 11(5):1238-1247. PubMed ID: 32083798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Long-term Efficacy of Sodium Glucose Co-transporter 2 Inhibitor in Patients with Non-alcoholic Fatty Liver Disease.
    Yamashima M; Miyaaki H; Miuma S; Shibata H; Sasaki R; Haraguchi M; Fukushima M; Nakao K
    Intern Med; 2019; 58(14):1987-1992. PubMed ID: 31308341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Hameed I; Hayat J; Marsia S; Samad SA; Khan R; Siddiqui OM; Khan MO; Malik S; Fatima K; Fudim M; Krasuski RA
    Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102111. PubMed ID: 36931466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
    Kuchay MS; Krishan S; Mishra SK; Farooqui KJ; Singh MK; Wasir JS; Bansal B; Kaur P; Jevalikar G; Gill HK; Choudhary NS; Mithal A
    Diabetes Care; 2018 Aug; 41(8):1801-1808. PubMed ID: 29895557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 11. Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease.
    Makri ES; Goulas A; Polyzos SA
    Eur J Pharmacol; 2021 Sep; 907():174272. PubMed ID: 34147478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis.
    Yan H; Huang C; Shen X; Li J; Zhou S; Li W
    Front Endocrinol (Lausanne); 2022; 13():923606. PubMed ID: 35909522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
    Euh W; Lim S; Kim JW
    Front Endocrinol (Lausanne); 2021; 12():613389. PubMed ID: 34177796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
    Wei Q; Xu X; Guo L; Li J; Li L
    Front Endocrinol (Lausanne); 2021; 12():635556. PubMed ID: 34220701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative effects of sodium-glucose cotransporter-2 inhibitors on liver functions in patients with nonalcoholic fatty liver disease.
    Chen X; Xu C; Hu K; Yang Y; Zhang YJ; Shi HZ; Gu Q; He SM; Zhang C; Wang DD
    Expert Rev Clin Pharmacol; 2023; 16(10):991-998. PubMed ID: 37669251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.
    Lin YH; Zhang ZJ; Zhong JQ; Wang ZY; Peng YT; Lin YM; Zhang HP; Tian JQ
    PLoS One; 2024; 19(5):e0302155. PubMed ID: 38701096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials.
    Bica IC; Stoica RA; Salmen T; Janež A; Volčanšek Š; Popovic D; Muzurovic E; Rizzo M; Stoian AP
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials.
    Gu Y; Sun L; Zhang W; Kong T; Zhou R; He Y; Deng C; Yang L; Kong J; Chen Y; Shi J; Hu Y
    Front Pharmacol; 2023; 14():1102792. PubMed ID: 36992825
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
    Mantovani A; Byrne CD; Scorletti E; Mantzoros CS; Targher G
    Diabetes Metab; 2020 Nov; 46(6):427-441. PubMed ID: 31923578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
    Ohki T; Isogawa A; Toda N; Tagawa K
    Clin Drug Investig; 2016 Apr; 36(4):313-9. PubMed ID: 26914659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.